-DOCSTART- -X- O
BACKGROUND -X- _ O
: -X- _ O
The -X- _ O
acute -X- _ O
respiratory -X- _ O
distress -X- _ O
syndrome -X- _ O
( -X- _ O
ARDS -X- _ O
) -X- _ O
is -X- _ O
characterized -X- _ O
by -X- _ O
the -X- _ O
acute -X- _ O
onset -X- _ O
of -X- _ O
hypoxemia -X- _ O
and -X- _ O
bilateral -X- _ O
lung -X- _ O
infiltrates -X- _ O
in -X- _ O
response -X- _ O
to -X- _ O
an -X- _ O
inciting -X- _ O
event -X- _ O
, -X- _ O
and -X- _ O
is -X- _ O
associated -X- _ O
with -X- _ O
high -X- _ O
morbidity -X- _ O
and -X- _ O
mortality. -X- _ O
Patients -X- _ O
undergoing -X- _ O
allogeneic -X- _ O
hematopoietic -X- _ O
stem -X- _ O
cell -X- _ O
transplantation -X- _ O
( -X- _ O
HSCT -X- _ O
) -X- _ O
are -X- _ O
at -X- _ O
increased -X- _ O
risk -X- _ O
for -X- _ O
ARDS. -X- _ O
We -X- _ O
hypothesized -X- _ O
that -X- _ O
HSCT -X- _ B-Patient
patients -X- _ I-Patient
with -X- _ I-Patient
ARDS -X- _ I-Patient
would -X- _ O
have -X- _ O
a -X- _ O
unique -X- _ O
transcriptomic -X- _ O
profile -X- _ O
identifiable -X- _ O
in -X- _ O
peripheral -X- _ O
blood -X- _ O
compared -X- _ O
to -X- _ O
those -X- _ O
that -X- _ O
did -X- _ O
not -X- _ O
undergo -X- _ O
HSCT. -X- _ O
METHODS -X- _ O
: -X- _ O
We -X- _ O
isolated -X- _ O
RNA -X- _ O
from -X- _ O
banked -X- _ O
peripheral -X- _ B-Intervention
blood -X- _ I-Intervention
samples -X- _ I-Intervention
from -X- _ O
a -X- _ O
biorepository -X- _ O
of -X- _ O
critically -X- _ O
ill -X- _ O
ICU -X- _ O
patients. -X- _ O
RNA-Seq -X- _ B-Intervention
was -X- _ O
performed -X- _ O
on -X- _ O
11 -X- _ O
patients -X- _ O
with -X- _ O
ARDS -X- _ O
( -X- _ O
5 -X- _ O
that -X- _ O
had -X- _ O
undergone -X- _ O
HSCT -X- _ O
and -X- _ O
6 -X- _ O
that -X- _ O
had -X- _ O
not -X- _ O
) -X- _ O
and -X- _ O
12 -X- _ B-Comparison
patients -X- _ I-Comparison
with -X- _ I-Comparison
sepsis -X- _ I-Comparison
without -X- _ I-Comparison
ARDS -X- _ I-Comparison
( -X- _ I-Comparison
5 -X- _ I-Comparison
that -X- _ I-Comparison
that -X- _ I-Comparison
had -X- _ I-Comparison
undergone -X- _ I-Comparison
HCST -X- _ I-Comparison
and -X- _ I-Comparison
7 -X- _ I-Comparison
that -X- _ I-Comparison
had -X- _ I-Comparison
not -X- _ I-Comparison
) -X- _ I-Comparison
. -X- _ O
RESULTS -X- _ O
: -X- _ O
We -X- _ O
identified -X- _ O
687 -X- _ O
differentially -X- _ O
expressed -X- _ O
genes -X- _ O
between -X- _ O
ARDS -X- _ O
and -X- _ O
ARDS-HSCT -X- _ O
( -X- _ O
adjusted -X- _ O
p-value -X- _ O
< -X- _ O
0.01 -X- _ O
) -X- _ O
, -X- _ O
including -X- _ O
IFI44L -X- _ O
, -X- _ O
OAS3 -X- _ O
, -X- _ O
LY6E -X- _ O
, -X- _ O
and -X- _ O
SPATS2L -X- _ O
that -X- _ O
had -X- _ O
increased -X- _ O
expression -X- _ O
in -X- _ O
ARDS -X- _ O
vs. -X- _ O
ARDS-HSCT -X- _ O
; -X- _ O
these -X- _ O
genes -X- _ O
were -X- _ O
not -X- _ O
differentially -X- _ O
expressed -X- _ O
in -X- _ O
sepsis -X- _ O
vs -X- _ O
sepsis-HSCT. -X- _ O
Gene -X- _ O
ontology -X- _ O
enrichment -X- _ O
analysis -X- _ O
revealed -X- _ O
that -X- _ O
many -X- _ O
differentially -X- _ O
expressed -X- _ O
genes -X- _ O
were -X- _ O
related -X- _ O
to -X- _ O
response -X- _ O
to -X- _ O
type -X- _ O
I -X- _ O
interferon. -X- _ O
CONCLUSIONS -X- _ O
: -X- _ O
Our -X- _ O
findings -X- _ O
reveal -X- _ O
significant -X- _ B-Outcome
differences -X- _ I-Outcome
in -X- _ I-Outcome
whole -X- _ I-Outcome
blood -X- _ I-Outcome
transcriptomic -X- _ I-Outcome
profiles -X- _ I-Outcome
of -X- _ I-Outcome
patients -X- _ I-Outcome
with -X- _ I-Outcome
non-HSCT -X- _ I-Outcome
ARDS -X- _ I-Outcome
compared -X- _ I-Outcome
to -X- _ I-Outcome
ARDS-HSCT -X- _ I-Outcome
patients -X- _ I-Outcome
and -X- _ I-Outcome
point -X- _ I-Outcome
toward -X- _ I-Outcome
different -X- _ I-Outcome
immune -X- _ I-Outcome
responses -X- _ I-Outcome
underlying -X- _ I-Outcome
ARDS -X- _ I-Outcome
and -X- _ I-Outcome
ARDS-HSCT -X- _ I-Outcome
that -X- _ I-Outcome
contribute -X- _ I-Outcome
to -X- _ I-Outcome
lung -X- _ I-Outcome
injury. -X- _ I-Outcome
ELECTRONIC -X- _ O
SUPPLEMENTARY -X- _ O
MATERIAL -X- _ O
: -X- _ O
The -X- _ O
online -X- _ O
version -X- _ O
of -X- _ O
this -X- _ O
article -X- _ O
( -X- _ O
10.1186 -X- _ O
/ -X- _ O
s12931-019-0981-6 -X- _ O
) -X- _ O
contains -X- _ O
supplementary -X- _ O
material -X- _ O
, -X- _ O
which -X- _ O
is -X- _ O
available -X- _ O
to -X- _ O
authorized -X- _ O
users -X- _ O
. -X- _ O

